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Abstract
Cystathionine β-synthase (CBS) deficiency has a wide clinical spectrum, rang-
ing from neurodevelopmental problems, lens dislocation and marfanoid fea-
tures in early childhood to adult onset disease with predominantly
thromboembolic complications. We have analysed clinical and laboratory data
at the time of diagnosis in 328 patients with CBS deficiency from the E-HOD
(European network and registry for Homocystinurias and methylation Defects)
registry. We developed comprehensive criteria to classify patients into four
groups of pyridoxine responsivity: non-responders (NR), partial, full and
extreme responders (PR, FR and ER, respectively). All groups showed over-
lapping concentrations of plasma total homocysteine while pyridoxine respon-
siveness inversely correlated with plasma/serum methionine concentrations.
The FR and ER groups had a later age of onset and diagnosis and a longer
diagnostic delay than NR and PR patients. Lens dislocation was common in
all groups except ER but the age of dislocation increased with increasing
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responsiveness. Developmental delay was commonest in the NR group while
no ER patient had cognitive impairment. Thromboembolism was the com-
monest presenting feature in ER patients, whereas it was least likely at presen-
tation in the NR group. This probably is due to the differences in ages at
presentation: all groups had a similar number of thromboembolic events per
1000 patient-years. Clinical severity of CBS deficiency depends on the degree of
pyridoxine responsiveness. Therefore, a standardised pyridoxine-responsiveness
test in newly diagnosed patients and a critical review of previous assessments is
indispensable to ensure adequate therapy and to prevent or reduce long-term
complications.
KEYWORD S
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delay
1 | INTRODUCTION
Homocysteine (Hcy) is a non-structural amino acid formed
during metabolism of the essential amino acid methionine
(Met). Hcy can be recycled back to Met by the remethylation
pathways or converted to cystathionine by cystathionine
β-synthase (CBS, EC 4.2.1.22) and next by γ-cystathionase to
the amino acid cysteine. Hcy and its disulfide, homocystine,
accumulate in the remethylation disorders and in CBS defi-
ciency, which is also known as classical homocystinuria
(OMIM # 236200). CBS deficiency was first identified by
selective screening for disorders of amino acid metabolism
in patients with cognitive impairment; these patients also
had skeletal abnormalities and lens dislocation.1-3 Further
research revealed pyridoxine responsiveness in some
patients with CBS deficiency.4 The CBS gene was mapped to
chromosome 21q22.3,5 and its coding sequence and genomic
organisation were subsequently characterised,6,7 allowing
the genetic basis of CBS deficiency to be identified.8,9
A natural history study of 629 patients revealed the typi-
cal clinical features in patients with pyridoxine responsive
and non-responsive CBS deficiency.10 The severe pyridoxine
non-responsive form typically presented in childhood with
cognitive impairment, lens dislocation, marfanoid features,
osteoporosis and thromboembolism, while the fully
responsive disease presented later with fewer problems
and partially responsive patients exhibited intermediate
severity. Measurement of total homocysteine (tHcy) in the
1990s led to ascertainment of adult patients with a milder
phenotype. Mudd and co-workers suspected that the mild
part of the spectrum was under-represented in this natural
history study and that some patients with the fully respon-
sive form might even remain asymptomatic.11 Recent
reports of adults with extreme pyridoxine responsiveness
have further expanded the phenotypic spectrum.12,13
CBS deficiency is diagnosed either by selective screen-
ing of symptomatic patients and high-risk family mem-
bers or, in some countries, by population-wide newborn
screening (NBS).14 For NBS, the primary markers are
usually Met or the methionine-to-phenylalanine ratio
followed in some programmes by second-tier tHcy test-
ing.14-17 Although tHcy can be used as the primary
screening marker, this is unlikely to be introduced widely
due to the longer analytical procedure and higher cost.
The key metabolite changes of CBS deficiency are marked
elevation of plasma tHcy with variable increases in Met
and decreases in cystathionine (determined by sensitive
mass spectrometric methods).12,18 The diagnosis is usually
confirmed by CBS assays in cultured skin fibroblasts or
serum/plasma, and/or by sequencing the CBS gene.
The European network and registry for Homo-
cystinurias and methylation Defects (E-HOD) started as
an EU-funded project in 2013. It is now an international
collaborative consortium involving 70 centres from all
over the world. One of its core activities is the E-HOD
registry, which collects pseudonymized data after
obtaining approval from local ethics committees and
informed consent from patients/legal representatives.
The E-HOD registry has already been used to describe
the natural history of remethylation defects19 and new-
born screening practices.14
In this study, we have analysed clinical and labora-
tory data for 328 CBS-deficient patients at the time of
enrolment into the E-HOD registry. We stratified this
cohort into four groups according to the degree of pyri-
doxine responsiveness and examined how this influenced
the clinical course and biochemical findings. This extended
natural history study supports the original notion of Mudd
and co-workers that CBS deficiency has an even wider
phenotypic spectrum than described before.
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2 | SUBJECTS AND METHODS
2.1 | Subjects, ethical issues and E-HOD
registry
As of February 28, 2019, the E-HOD registry contained data
on 337 individuals with diagnosis of CBS deficiency
reported by the different centres. This registry was first
approved by the Ethics Committee of University Hospital in
Heidelberg (No. S-525/2010; 14.3.2013). All participating
centres received approval from their local ethics committees
before enrolling patients and all patients provided written
informed consent before pseudonymized data were entered
into the registry. The EHOD registry documents natural his-
tory (symptoms by organs), biochemical and treatment
data. It records intelligence and developmental scores (IQ,
DQ) from age-appropriate standardised instruments.
Standardised self- and proxy report questionnaires inform
about neuropsychological development and behaviour. In
2017, the participating centres were asked for permission to
use the data of the CBS deficient patients for analysis and
publication, and the project was approved by the E-HOD
Steering Committee. Analysis of data and publication of
results was also approved by the Ethics Committee of the
General University Hospital in Prague (No 417/20 S-IV).
2.2 | Definition of pyridoxine
responsiveness
Pyridoxine responsiveness was originally defined in the
literature as the disappearance of non-protein-bound
homocyst(e)ine from plasma after a loading test with pyr-
idoxine.4,20 The lower limit of detection for this mix of
Hcy-containing compounds using an amino acid analyser
corresponds to a total homocysteine (tHcy) of about
50-60 μmol/L,21 and a decrease of tHcy to <50 μmol/L on
treatment with pyridoxine was subsequently used to
define full responsiveness in a standardised test.18 The E-
HOD registry originally offered selection of pyridoxine
responsiveness in categories NO/YES/UNKNOWN, how-
ever, the criteria were not defined clearly, and data on
tHcy during the pyridoxine loading test were not avail-
able. A new means of categorisation of responsivity was
needed to ensure consistency, and we have therefore
developed new surrogate criteria for assessing the degree
of pyridoxine responsiveness even in the absence of a
standardised pyridoxine test. We defined pyridoxine non-
responsiveness (NR), partial responsiveness (PR), full
responsiveness (FR) and, in addition, a new form of
extreme responsiveness (ER) requiring only small dose of
pyridoxine daily.12 Consistent with the definition of Morris
et al,18 the major criterion for FR and ER was the lowering
of plasma tHcy to <50 μmol/L with pyridoxine administra-
tion alone (below ≈1 mg/kg/d in ER; above ≈1 mg/kg/d in
FR). Treatment with diet and/or betaine were considered
indicators of NR or PR. NR patients seldom achieve tHcy
<100 μmol/L without a low-methionine diet (ie, a diet
extremely low in natural protein with methionine-free
amino acid supplements) but some late diagnosed patients
cannot manage this diet and are only treated with betaine.
The degree of methionine restriction and tHcy levels on
therapy were used to help distinguish NR and PR patients.
For details see Table 1.
2.3 | Data verification
Following a preliminary analysis of registry data in 2017,
we modified the registry entries on pyridoxine responsivity
to include all four categories and we sent emails to all col-
laborators with a request to update their data in January
2019. Data from the registry were extracted on February
28, 2019. Subsequently for each of the 337 patients, we
assessed the consistency of the declared pyridoxine res-
ponsivity with the dose, additional treatment and tHcy
levels achieved; in patients with discrepant findings, plausi-
bility was checked against genotypes with known res-
ponsivity. Of the 337 patients we excluded nine individuals
in whom we were unable to determine pyridoxine res-
ponsivity due to missing data and/or no reply from contrib-
utors. Based on communication between the data analysis
team and the contributing centres, we reclassified res-
ponsivity in 62 patients, with the final approval by the con-
tributors. The reasons for reclassification in each patient are
shown in Table S1. In collaboration with contributing cen-
tres we also classified responsivity in 71 additional patients
for whom the relevant data were originally missing.
Next, we checked the plausibility of the age of onset,
age of diagnosis, and of protein and Met intake, betaine
and pyridoxine doses, weight and the correct nomencla-
ture of genetic variants. In September 2019, we emailed
two-page extracts from records of a subset of 308 patients
with specific questions on implausible and/or outlying
data, and with a request to provide any missing key data.
Clarification of data in question proceeded via bi-
directional email communication until October 31, 2019.
Despite all these attempts we did not receive the
requested information on 26 patients; using a consensus
evaluation by VK and JS we excluded implausible or
severely outlying data on diet (n = 3, for example, Met
and amino acid mixture intake 562 mg/kg/day and 20
g/kg/day, respectively) and plasma tHcy levels (n = 4, for
example, free homocystine concentrations of 103 μmol/L
instead of tHcy on therapy). The cleaned dataset was
deposited into a local database and used for all analyses.
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2.4 | Plasma CBS assay
The E-HOD registry contained data on plasma CBS activity
in 30 patients. Participating centres were invited to collect
plasma from consenting patients and ship them to the Met-
abolic Centre of Department of Pediatrics and Inherited
Metabolic Disorders in Prague for the determination of
plasma CBS activity using a published method.22,23 In this
way CBS activity was measured in an additional 34 patients
from 10 centres. A total of 71 plasma CBS activities from
64 patients on and/or off treatment with pyridoxine were
available for statistical analyses.
2.5 | Statistical analysis
Continuous variables are presented as means with SD or
median with interquartile ranges, wherever appropriate. Cate-
gorical variables are shown in absolute and relative frequencies.
Differences between responsiveness groups were
tested in two ways: (1) for the overall difference between
the groups and (b) for the linear trend with the groups
ordered as non-responder – partial – full – extreme
responder. For categorical variables, the overall differ-
ence was tested using Fisher exact test and the linear
trend was assessed by the linear-by-linear association
test. For continuous variables, the overall difference was
tested using Kruskal-Wallis nonparametric ANOVA and
the linear trend was tested using the univariate linear
regression with responsiveness as a linear factor.
Kaplan-Meier time-to-event graphs were constructed for
lens dislocation and thromboembolic events. Since data on the
exact occurrence of these events were not available, patients
were censored at the time of diagnosis if lens dislocation or a
thromboembolic event had already occurred. Overall differ-
ence and pairwise differences among responsiveness groups
was tested by log-rank test; the Benjamini-Hochberg method
was used to control for multiple comparisons.
Statistical language and environment R, version 3.6.3
was used throughout the analysis. The level of statistical
significance was set at 0.05.
3 | RESULTS
3.1 | Study population and mode of
ascertainment
Data from the E-HOD registry (https://ehod-registry.org/)
were analysed for 328 patients with CBS deficiency and veri-
fied degrees of pyridoxine responsiveness, entered by 57 cen-
tres from 19 countries (Figure 1, panel A and Table S2).
Overall, 62% of patients were NR, 20% PR, 12% FR,
and 6% ER.
TABLE 1 Criteria for assessing pyridoxine responsiveness in treated individuals with CBS deficiency
Non-responder Partial responder Full responder Extreme responder
Standardised 6-week test according to Morris 2017




















No restriction No restriction
Betaine Usually administered
in adults and older
children
Sometimes used No betaine No betaine
Combination of
diet and betaine
Often Can be only diet, only
betaine or
combination of both
Pyridoxine doses Often given, does not
imply benefit
Up to 10 mg/kg/d in
infants and children;
typically in the range
of 2–5 mg/kg/d in
adults
> ≈ 1 mg/kg/d <≈1 mg/kg/d
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Table 2 shows a summary of data for the patients at
diagnosis and at registry enrolment. At registry enrol-
ment the median age of patients was 26 years with a total
of 9131 patient-years. The majority of patients were white
(92%). The male-to-female ratio of 1.13:1 for the entire
cohort was consistent with the known autosomal reces-
sive inheritance, however, sex ratio deviated from 1:1 in
different groups of responsiveness (P = .0069). Group of
NR and PR contained more males while the FR and ER
groups contained more females.
Table 2 shows the body mass index (BMI) in patients
>18 years of age and Figure S1 shows BMI after stratifica-
tion for different age and pyridoxine responsiveness cate-
gories. NR patients aged 18-30 years had the lowest
median BMI at 22.6 kg/m2 whilst ER patients aged
>50 years had a median BMI of 31.9 kg/m2 (P < .0001).
The increase in BMI with pyridoxine responsiveness
remained significant after regression analysis using age
and sex as covariates (P < .001).
Patients were ascertained mostly by selective screen-
ing among symptomatic patients (72%) followed by
screening among high-risk family members (15%; this
included also one patient diagnosed prenatally), and by
NBS (13%). The proportion of patients with different
degrees of responsiveness was similar in those
ascertained clinically and by high-risk family screening
(Figure 1, panel B), however there were no FR or ER
among 43 patients ascertained by NBS. Patients were
diagnosed between 1962 and 2018; the majority of
patients (88%) were diagnosed after year 1983
(Figure S2).
3.2 | Confirmatory testing and
laboratory findings
Solely metabolite analysis was reported in 25% of
patients, while confirmatory enzymatic testing and DNA
analysis were done in 27% and 69% of patients, respec-
tively. Different combinations of confirmatory laboratory
tests were observed in this cohort (Figure S3).
We analysed the biochemical markers at the time of
diagnosis in patients for whom the data were available
(Table 2 and Figure 1, panel C). Plasma tHcy did not dif-
fer significantly among the four responsiveness groups
(range of medians 226-262 μmol/L; range of tHcy 29.9–-
550 μmol/L) at diagnosis. Similarly, free homocystine
with a median of 48 μmol/L did not differ among the
responsiveness groups. In contrast plasma or serum Met
decreased significantly with increasing responsiveness;
the median was 440 μmol/L in NR, 313 μmol/L in PR,
103 μmol/L in FR and 60 μmol/L in ER.
Data on enzymatic activity were available for only
89 patients (33 values in fibroblasts and 71 values in
plasma of patients). CBS activity in fibroblasts is not sup-
posed to be influenced by pyridoxine treatment of the
patient because the cells will have been exposed to the
same pyridoxine concentration in the culture medium.
Pyridoxine administration can, however, increase the
activity of mutant CBS released from the liver into the
circulation probably due to improved folding, particularly
in FR and ER (Table 2 and Figure 1, panel D). Thus,
although there was an increase in median fibroblast CBS
activities from NR, PR and FR (0.0, 1.5, and 4.0% activity
in controls, respectively) and in median plasma CBS
activity from patients off pyridoxine (either taken at diag-
nosis or during periods of non-compliance or after short
FIGURE 1 Geographical distribution of responsiveness groups
and biochemical findings at diagnosis. A, Number of patients per
country; B, mode of ascertainment; C, total homocysteine and
methionine at diagnosis; and D, CBS activity in fibroblasts and
plasma. Data are stratified by degree of responsiveness, NR, non-
responders; PR, partial responders; FR, full responders; ER,
extreme responders. Bar graphs in Panels A and B show numbers
and proportion of patients with different responsivity, respectively.
Horizontal bars in Panels C and D indicate the medians. If plasma
CBS activities were measured on and off pyridoxine, the results are
connected with diagonal lines. Fibroblast and plasma CBS activities
are shown as % of median of controls
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pyridoxine wash-out periods), these did not reach statisti-
cal significance (0% control activity in NR, 4.5% in PR,
7.5% in FR and 5% in ER). In plasma from patients taking
pyridoxine, however, there was a clear and statistically
significant increase of CBS activities, especially in FR and
ER (0% of activity of controls in NR, 3% in PR, 45% in FR,
and 73% in ER).
Since detailed analysis of genetic variants and of the cor-
relation between genotype and phenotype will be the subject
of a future study, we present here only the geographic distri-
bution of the five commonest alleles for which the pyridox-
ine responsivity is known (ie, p.Thr191Met, p.Gly307Ser,
and p.Trp409_Gly453del associated with non-responsive-
ness, and p.Ile278Thr and p.Ala114Val associated with
responsiveness). The p.Thr191Met was most frequent in
Spain, p.Gly307Ser in Ireland and p.Trp409_Gly453del
in the Czech Republic, p.Ala114Val in Switzerland
and p.Ile278Thr in the Netherlands; for details in
other countries see Table S2.
3.3 | Natural history in clinically
ascertained patients
Two hundred and thirty-one patients were clinically
symptomatic and diagnosed by selective screening. We
analysed the diagnostic delay and salient clinical fea-
tures for the complete group as well as within and
between the subgroups of patients with different
degrees of pyridoxine responsiveness (Table 3, detailed
data Table S3).
3.3.1 | Age at presentation, age at
diagnosis, and diagnostic delay
The first clinical symptoms were noted at a median age of
4.4 years in the NR group and increased significantly with
the degree of responsiveness to 21 years in ER. The degree
of responsiveness also correlated significantly with age at
diagnosis and diagnostic delay (defined as the time between
the age of first symptoms and the age of diagnosis)
(Figure 2A). These data clearly show that patients with the
milder FR and ER forms present later in life and experience
a much longer diagnostic delay compared to patients with
the early childhood NR and PR types of CBS deficiency.
3.3.2 | Typical clinical constellations and
degrees of pyridoxine responsiveness
The typical clinical symptoms of CBS deficiency include
central nervous system (CNS) problems (eg, developmental
delay, learning difficulties and psychiatric disturbances);
thromboembolic events in various vascular beds; connective
tissue abnormalities resulting in skeletal abnormalities
(marfanoid features, kyphoscoliosis, genua valga, osteoporo-
sis) and/or abnormal zonular fibres, which cause lens dislo-
cation. We analysed which combinations of clinical
symptoms at diagnosis were typically present in the patient
subsets. The NR and PR patients exhibited a high propor-
tion of CNS symptoms combined with lens dislocation; FR
patients presented most frequently with lens dislocation
and thromboembolism while isolated thromboembolism
FIGURE 2 Onset of symptoms, diagnostic delay and
combination of symptoms in untreated patients. A, Age at
presentation and diagnosis, and B, combination of affected systems
in clinically ascertained patients. Data are stratified by the degree of
responsiveness, NR, non-responders; PR, partial responders; FR,
full responders; ER, extreme responders. Horizontal bars in panel A
indicate the medians. Panel B, Venn diagrams showing the
combination of clinical complications; numbers indicate
percentages for each responsiveness group
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was the predominant presenting symptom in ER patients
(Figure 2B). For more details on the connective tissue
abnormalities (ie, skeletal and ocular complications) see
Table S3.
3.3.3 | Developmental delay and
learning difficulties
Developmental delay and/or learning difficulties were pre-
sent at diagnosis in 53% of NR, 30% of PR, and 17% of FR
patients while none of these symptoms were reported in the
ER patients. The differences in the frequency of develop-
mental delay between groups were statistically significant.
3.3.4 | Testing of intelligence &
developmental quotients (IQ and DQ)
was done using variable methods in 31 patients following
registry entry; no quantitative data at diagnosis were avail-
able. Data from six patients were uninterpretable and thus
excluded from the analysis. Of the remaining 25 patients,
five had normal, 10 below average and 10 low or very low
intelligence. Owing to the variable data sources and time
points of testing, questionable data quality, skewed distribu-
tion towards lower intelligence (indicating a selection bias),
and the small number of cases, no further subgroup or
other statistical analyses were conducted.
In contrast, there was no significant difference among
the responsiveness groups for the frequencies of psychiat-
ric disease (present in 12% of all patients). Data on behav-
ioural testing after registry enrolment were available for
50 patients. The test results followed a similar distribu-
tion for all four of responsiveness (median between four
and six behavioural problems on a 20-item scale). Mean-
ingful statistical analysis of correlations with cognitive
function test results was not possible as these test results
were widely scattered and only available for 31 patients.
Details of other neurological, psychiatric and behavioural
complications are shown in Table S3.
3.3.5 | Behaviour and well-being
Fifty-one patients had at least one self-assessment or
parental assessment of 33 behavioural problems between
enrolment and data extraction (total: 98 assessments; 1-5
measurements per individual). In total 367 items (21% of
possible events) were marked. Symptoms indicated at
least once per person were counted as events (repeated
items were not counted) to give a general overview of the
type of behavioural problems perceived by patients with
CBS deficiency or their parents. The main complaints
were shyness (53% of 51 patients), anxiety (51%), short
attention span (51%), distractibility (47%), sleep problems
(51%), hyperactivity (33%), and pain (31%). We did not
undertake more detailed evaluation of severity, clustering
of symptoms in individuals, differences between self- and
parental assessments or correlation with cognitive ability
because of the variability of the assessments and the
small sample size.
3.3.6 | Detailed analysis of
thromboembolism
Thromboembolic complications included stroke (14/36
of which were caused by sagittal sinus thrombosis),
deep venous thrombosis and pulmonary embolism (for
details see Table S3). The proportion of patients with a
history of thromboembolic events reported at the time
of diagnosis increased significantly with pyridoxine
responsiveness from 27% in the NR to 73% in the ER
group (P = .0087). This is due to the older age of
responsive patients at diagnosis: the number of throm-
boembolic events per 1000 patient-years was very simi-
lar in all four responsiveness groups (ranging from 21.9
to 32.6 events). Indeed, time-to-event analysis showed
that the 50% likelihood of having experienced a throm-
boembolic event by the time of diagnosis was reached
at a significantly earlier age in pyridoxine non-
responders (18 years) than in the other three groups
(33, 30, and 35 years of age in PR, FR, and ER, respec-
tively, Figure 3, panel A).
3.3.7 | Detailed analysis of connective
tissue abnormalities
Skeletal anomalies were present in 59% of NR patients
and the frequency decreased progressively with pyridox-
ine responsiveness to 27% in ER. The frequency of lens
dislocation by the time of diagnosis also fell with respon-
siveness (88% in NR decreasing to 27% in ER). A 50%
probability of lens dislocation was reached at 8, 14, and
27 years in NR, PR, and FR patients, respectively
(Figure 3, panel B). ER patients only reached a 40% prob-
ability for lens dislocation at the age of 74 years. Extreme
responders and NR differed significantly from all other
groups whilst the difference between FR and PR did not
reach statistical significance. Data normalised by patient-
years show similar results, decreasing from 79.6 per 1000
patient-years in NR to only 4.7 in ER.
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3.3.8 | Other complications
Feeding problems were reported for 11% of patients, sei-
zures for 19% of patients and cardiac disease (mostly
hypertension, mitral valve insufficiency or aortic aneu-
rysm) for 9% of patients in the cohort; there were no sta-
tistically significant differences among the responsiveness
groups. For details see Table S3.
4 | DISCUSSION
In this paper, we studied the pyridoxine responsiveness
and its impact on the biochemical and clinical diversity
in 328 individuals with CBS deficiency from the E-HOD
registry. The disease shows a wide phenotypic spectrum,
ranging from a severe disease with onset during early
childhood presenting mostly with CNS, ocular and skele-
tal involvement to an adult onset disease with predomi-
nantly thromboembolic complications.
In many respects, the current cohort of 328 patients
resembles the cohort of 629 patients in Mudd's landmark
natural history study.10 Both cohorts were mainly rec-
ruited by metabolic physicians, who were asked to collect
standardised data, but Mudd's series also included
97 patients from the literature. All of our patients were
alive whereas Mudd included 64 deceased patients. Both
cohorts were international; most of our patients are from
Europe. Mudd did not state the country of origin but a
larger proportion from the United States is likely. There
is unlikely to be much overlap between the two series as
Mudd's data were collected in 1982-3 whereas only 12%
of our patients were diagnosed before 1984.
For inclusion in Mudd's series, patients were required
to have lens dislocation, hypermethioninaemia or enzy-
matic confirmation in addition to increased homocystine
excretion; CBS deficiency was confirmed by enzymology
in one third, but the other patients only had metabolite
measurements. We used different criteria to avoid exclud-
ing the recently described group of patients with an
extremely marked response to pyridoxine.12,24 CBS defi-
ciency was confirmed by enzymology or DNA analysis in
most patients; the clinical features, plasma free Hcy/tHcy
and methionine concentrations, and therapy were
reviewed in the others to ensure the plausibility of the
diagnosis.
Our series differs from Mudd's in two main respects.
First, more adult patients are now diagnosed after pre-
senting with thromboembolism; this has led to the recog-
nition of a wider range of pyridoxine responsive forms.
The other main difference is the new multifactorial clas-
sification of pyridoxine responsiveness in our study.
Mudd relied on his collaborators to judge pyridoxine res-
ponsivity. At that time, fully responsive patients were
generally considered to be those who ceased to have
detectable free homocystine in blood when taking pyri-
doxine. Of Mudd's 629 patients, 231 (37%) were classified
as responsive, 231 (37%) as non-responsive, and 67 (11%)
as intermediate in response (100 were not classified).
Nowadays, pyridoxine responsiveness can be assessed
by a standardised test,18 but this test has only recently
been widely used. Patients in the E-HOD registry had,
therefore, been classified as non-responsive, partially or
fully responsive using various undefined criteria. Many
patients who were said to be pyridoxine responsive had
marked fluctuations in tHcy concentrations whilst on
long-term pyridoxine or needed additional forms of treat-
ment, indicating that assessments in different centres
FIGURE 3 Time-to-event graphs of thromboembolism and
lens dislocation in untreated clinically ascertained patients. A,
Presence and/or history of thromboembolism and B, presence
and/or history of lens dislocation. Curves were constructed by the
method of Kaplan and Meier, patients were censored at the age of
diagnosis if lens dislocation or thromboembolic event were present
at diagnosis and/or were recorded in patients´ histories. Data are
stratified by degree of responsiveness, NR, non-responders; PR,
partial responders; FR, full responders; ER, extreme responders
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were not comparable. We have, therefore, developed a set
of biochemical and clinical criteria for defining the
degree of responsiveness retrospectively in this series. In
particular, supplementation of pyridoxine alone should
maintain plasma tHcy below 50 μmol/L in FR and ER,
whereas a severe methionine restriction is required to
control tHcy in NR. According to this classification most
of the patients in our cohort were NR (62%) or PR (20%),
while FR and ER comprised only 12% and 6%, respec-
tively. The proportion of non-responders was consider-
ably higher than in Mudd's series, which may seem
surprising as we would now expect more recognition of
mild patients presenting as adults, often with thrombo-
embolism. In part, this may be a result of the recent
implementation of newborn screening programmes,
which detect primarily non-responsive patients and miss
less severe cases. The numbers may also reflect the more
rigorous assessment of responsiveness in our series. The
main reason, however, is probably that the proportions of
different responsiveness groups in the E-HOD registry
reflects the patients seen by the metabolic centres partici-
pating in E-HOD. This is unlikely to be a true reflection
of the proportions of different responsiveness groups in
the whole population due to a selection bias. Severely
affected patients requiring dietary treatment are likely to
attend a specialist metabolic centre for detailed monitor-
ing and advice whereas mildly affected adults, who only
need pyridoxine to control their disease, will often be
managed locally by non-specialist physicians, who are
less likely to participate in E-HOD.
The proportions of different responsiveness groups
varied markedly between countries in the E-HOD regis-
try (Figure 1A). We hypothesise that two factors may
have contributed to the observed geographic differences.
The first is the regional variation in the prevalence of
alleles conferring different degrees of pyridoxine respon-
siveness (eg, the high frequency of the pyridoxine-
responsive variant p.Ile278Thr in the Netherlands and
high frequency of the pyridoxine non-responsive variants
p.Thr191Met and p.Gly307Ser in Spain and Ireland,
respectively). The second factor relates to the lower likeli-
hood of pyridoxine responsive patients being entered into
the E-HOD registry, as discussed in the previous para-
graph; the proportion enrolled will vary between coun-
tries depending on who manages these patients.
The categorisation into four groups of pyridoxine
responsiveness is useful as these groups differ in many
phenotypic aspects. In general, the disease severity is
milder and age of onset older in pyridoxine responsive
patients than in NR and PR, and the combinations of
affected organ systems are different.
Lens dislocation was a common presenting symptom
in all categories except the ER group but the age at lens
dislocation increased with the degree of pyridoxine
responsiveness. In his series, Mudd also found earlier
lens dislocation in non-responsive than responsive
patients, though they occurred at younger ages in both
groups (50% probability at 6 and 10 years, respectively).
The risk of thromboembolism is greatly increased in
individuals with CBS deficiency compared to the general
population. The risk of venous thrombosis in the general
population is higher in males and increases substantially
with age, from 0.03 events per 1000 individuals per year
in children to 0.2 in young adults, 0.9 in middle aged
adults and up to 12 events per 1000 individuals per year
in older adults.25-27 In the E-HOD cohort, CBS deficient
patients experienced 18.7-26.8 thromboembolic events
per 1000 patient-years, giving a relative risk at least
20-fold higher than the general population for middle
aged adults and 1000-fold higher in children. These
data indicate that tHcy should be included in algorithms
for the investigation of individuals with thromboembolic
events. Though thromboembolism was a commoner pre-
senting feature in our FR and ER groups, this was just
because they were older and did not reflect a higher risk:
the number of events per 1000 patient years was similar
in all groups. Indeed, thromboembolic events tended to
occur at a younger age in the NR group than the others
(50% probability at 18 years in NR, 31-36 years in the
other groups). Mudd made similar observations in his
series (50% probability at 24 years in non-responders,
28 years in responders).
In CBS deficiency, plasma tHcy is generally consid-
ered to be responsible for the thrombotic diathesis while
the contribution of other metabolic disturbances is
largely unknown. Thromboembolism is also a major pre-
senting symptom in adolescent and adult patients with
late-onset remethylation defects and comparable tHcy
levels.19 In the cohort of CBS deficient patients, however,
tHcy levels at diagnosis were similar in all responsiveness
categories, although thromboembolism occurred at a
much later age in ER than in NR. If tHcy is the culprit,
why should ER patients require a higher long-term tHcy
exposure before a thromboembolic event than NR
patients? The question cannot be answered from this ret-
rospective study but tHcy values may not be stable in ER
patients without treatment, instead varying with nutri-
tion or the intake of commonly available vitamin supple-
ments. The latter often contain pyridoxine doses that
may correct the raised tHcy levels in ER and FR patients.
By masking the diagnosis, this may contribute to the long
delay in diagnosing these patients. While diagnosis is
often delayed in all forms of CBS deficiency, the delay
was longest in the FR and ER groups. This must also
have been partly because thromboembolism is a less spe-
cific symptom than lens dislocation.
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Newborn screening (NBS) is of outstanding value for
severely affected patients, and particularly useful in
populations with a high prevalence of severe cases such
as Ireland or Qatar. As one might expect, FR and ER
patients had higher residual plasma CBS activity than
NR and PR patients and lower Met concentrations at pre-
sentation. NBS for homocystinuria is almost universally
based on initial detection of raised Met concentra-
tions14,17 and consequently none of the FR or ER patients
in this series were detected by NBS.
The lower Met levels and higher residual activity of
liver-derived plasma CBS in FR and ER patients suggest
that more Hcy is removed via the transsulfuration path-
way and less is recycled to Met. These findings support
the hypothesis that impaired transsulfuration and
decreased cysteine (Cys) formation may play a critical
role in the pathophysiology of CBS deficiency,28 possibly
including also CNS involvement.
Patients with CBS deficiency were originally
described as being lean and thin, especially in child-
hood.29 In a more recent small study patients showed sig-
nificantly lower lean mass index but the fat percentage
was not significantly different from controls.30 Another
study found that accelerated growth ceases before
puberty and does not result in an increased final height
or an abnormal BMI in adulthood.31 In our study the
BMI data collected on registry enrolment (during treat-
ment) showed that the BMI in adult individuals increases
with degree of pyridoxine responsiveness from a median
of 22.9 kg/m2 in NR to a median of 28.4 kg/m2 in ER. It
is unclear whether this observation is caused by differ-
ences in the duration of normal diet prior to diagnosis,
differences in the severity of natural protein restriction or
possibly by different degrees of Cys depletion in the vari-
ous forms of CBS deficiency. In the general population, it
has been shown that the plasma total cysteine concentra-
tion (tCys) correlates positively with BMI and fat mass
content.32 In several mouse models CBS deficiency was
associated with decreased body fat mass33,34; this change in
body composition was corrected by methionine restricted
diet or enzyme replacement therapy but not by N-
acetylcysteine administration.35,36 Due to the absence of
data on tCys concentrations in the E-HOD registry we were
unable to explore whether BMI was related to the extent of
Cys depletion in various forms of homocystinuria.
CBS deficiency has a continuous wide spectrum of
symptoms and pyridoxine responsiveness is also a contin-
uous variable. Responsiveness has been categorised in
this and earlier studies for the sake of simplicity and clar-
ity and to allow recommendations on treatment. The
mainstays of treatment for CBS deficiency are still a
methionine-restricted diet in non-responsive patients and
pyridoxine administration in responsive patients. Betaine
may be added to lower tHcy (at the cost of increasing
Met). Precise assessment of pyridoxine responsiveness at
diagnosis is mandatory to tailor the available treatment
options to the patient's needs and to avoid overtreatment,
for example with pyridoxine in non-responders or diet in
patients adequately controlled by pyridoxine alone.
This work has some limitations related to selection
bias. First, the E-HOD research initiative encompasses
centres that are especially interested in the homo-
cystinurias and methylation disorders and willing to
invest time entering their patients' data into the registry.
Moreover, E-HOD was not originally a worldwide project
and coverage of cases within countries remains variable.
Second, subjects have been enrolled at variable ages and
times after diagnosis, when centres joined the registry.
Due to the retrospective nature of the study and despite
careful data cleaning, a certain amount of inaccuracy of
the history, clinical observation and treatment data must
be expected. Furthermore, the lack of harmonisation and
standardisation within laboratories probably creates
some inaccuracy in biochemical parameters. Finally, data
on cognitive abilities, behavioural problems and quality
of life have only been collected in a very limited number
of subjects because psychological assessments and patient
reported outcomes have not yet been fully integrated into
the care for patients with classical homocystinuria.
In summary, data from our study show that the new
proposed categories of pyridoxine responsiveness are
associated with different clinical severities and patterns
of symptoms. Re-assessing pyridoxine responsiveness
may have important therapeutic consequences.
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